

# Impulse Oscillometry for Leukotriene D<sub>4</sub> Inhalation Challenge in Asthma

Wei Jie Guan PhD, Jin Ping Zheng MD, Yi Gao MMed, Cai Yu Jiang, Xu Shi PhD, Yan Qing Xie PhD, Qing Xia Liu MMed, Mei Jiang PhD, Jia Ying An MT, Xin Xin Yu MT, Wen Ting Liu MT, Li Ping Zhong MT, Zhong Ping Wu MT, and Nan Shan Zhong MD

**BACKGROUND:** The value of impulse oscillometry (IOS) for bronchial provocation testing is poorly defined. We investigated the positive threshold derived from the parameters and diagnostic power of IOS for asthma with the leukotriene D<sub>4</sub> bronchial provocation test. **METHODS:** We enrolled 62 subjects with asthma and 21 healthy subjects. IOS was employed to perform the leukotriene D<sub>4</sub> bronchial provocation test, followed by spirometry. The positive threshold was determined based on the cutoff point in the receiver operating characteristic curve, from which the parameters with the highest diagnostic power were obtained. **RESULTS:** Airway impedance at 5 Hz (Z<sub>5</sub>), resistance at 5 Hz (R<sub>5</sub>), and resonance frequency had the highest diagnostic power (areas under curve 0.82, 0.82, and 0.81, respectively), with increases of 57%, 43%, and 63%, corresponding to a 20% decrease in FEV<sub>1</sub>, respectively. IOS indices yielded assay sensitivity and specificity similar to that of spirometry. The positive threshold for IOS, defined as either a 57% increase in Z<sub>5</sub> or a 63% increase in resonance frequency in the bronchial provocation test, yielded an assay accuracy of 0.6 in subjects with asthma. **CONCLUSIONS:** IOS during the leukotriene D<sub>4</sub> bronchial provocation test has a diagnostic power similar to that of spirometry. Either a 57% increase in Z<sub>5</sub> or a 63% increase in resonance frequency may be regarded as a surrogate of FEV<sub>1</sub> decrease to determine airway hyper-responsiveness in asthma. *Key words:* impulse oscillometry; airway resistance; resonance frequency; leukotriene D<sub>4</sub>; bronchial provocation test; asthma. [Respir Care 2013; 58(12):2120–2126. © 2013 Daedalus Enterprises]

## Introduction

Cysteinyl leukotrienes are potent inflammatory mediators that elicit bronchoconstriction, leading to air-flow lim-

itation,<sup>1-3</sup> which could be blocked by leukotriene receptor antagonists.<sup>4</sup> Unfortunately, a simple and feasible measure for predicting the efficacy in asthma is lacking. Bronchial provocation test has been extensively applied for measurement of airway responsiveness.<sup>5</sup> Conventional stimuli (ie, methacholine) could not specifically discriminate the ef-

---

The authors are affiliated with the State Key Laboratory of Respiratory Disease, China Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China, with the exception of Cai Yu Jiang, who is affiliated with Sichuan People's Hospital, Chengdu, Sichuan, China.

Dr Zheng was partly supported by grant 915280000100019 from the Provincial Natural Science Foundation of Guangdong, grant ITR0961 from the Changjiang Scholars and Innovative Research Team in University, and grant 2012BAI05B01 from the National Key Technology Research and Development Program of the 12th National Five-Year Development Plan. Dr Gao was partly supported by grant 2009J1-C321-1 from the Municipal Science and Technology Plan of Guangzhou, grant

---

2009-YB-143 from the Guangzhou Leading Project for Medicine and Health, and grant 2008A02 from the Scientific Project of Guangzhou Medical University. The other authors have disclosed no conflicts of interest.

Correspondence: Jin Ping Zheng MD, State Key Laboratory of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, Guangdong, China, 510120. E-mail: jpzhenggy@163.com.

DOI: 10.4187/respcare.02417

ficacy of leukotriene receptor antagonist, which might be assessed, at least theoretically, by using leukotriene D<sub>4</sub> for the bronchial provocation test.<sup>6-15</sup>

Although spirometry has been the recommended method for assessing bronchial provocation, repetitive forced inhalation might result in bronchodilation, leading to false negative results. Impulse oscillometry (IOS), a novel lung function testing method characterized by shorter test duration,<sup>16,17</sup> minimal requirements to subjects, and low likelihood of bronchodilation, does not influence airway smooth muscle tone. Theoretically, IOS parameters correlate negatively with airway caliber, as evidenced by the fact that bronchospasm significantly increases airway impedance, resistance, and resonance frequency, and reduces airway capacitance,<sup>18</sup> which suggests that IOS may be a surrogate for spirometry. However, the lack of gold standard test has rendered it difficult to be clinically applied. We investigated the discriminative and significant thresholds of IOS and its diagnostic potential in the detection of asthma with the leukotriene D<sub>4</sub> bronchial provocation test.

## Methods

The study protocol was approved by the ethics committee of First Affiliated Hospital of Guangzhou Medical University. All subjects gave written informed consent prior to participation in the study.

## Subjects

Asthma was diagnosed based on the Global Initiative for Asthma 2006 guideline.<sup>19</sup> Consecutive patients with asthma who visited the clinics at First Affiliated Hospital of Guangzhou Medical University between March and August 2010 underwent screening. The inclusion criteria were age 18–65 years, no respiratory-tract infection in the past 2 weeks, normal chest radiography, and baseline FEV<sub>1</sub> > 60% of predicted. We excluded patients whose FEV<sub>1</sub> decreased ≥ 20% after ethanol dilution challenge, who had other confirmed lower airway or severe systemic diseases, and who had poor adherence.

We asked the subjects not to use leukotriene receptor antagonist for 5 days, oral corticosteroid or antihistamine for 3 days, oral xanthenes or long-acting bronchodilators for 2 days, inhaled corticosteroid or long-acting bronchodilator for 24 hours, and short-acting bronchodilator for 4 hours prior to the measurements.

The healthy subjects were 18–65 years old, and had no upper-respiratory-tract infection for the previous 2 weeks, no allergic or systemic diseases, normal chest radiograph, and regular spirometry values.

## QUICK LOOK

### Current knowledge

The diagnostic power of impulse oscillometry for bronchial provocation tests, compared with spirometry, remains elusive in asthma. There is a need to define the positive threshold of impulse oscillometry parameters with high diagnostic power.

### What this paper contributes to our knowledge

Impulse oscillometry showed acceptable diagnostic power, compared with spirometry, for bronchial provocation testing. A 57% increase in airway impedance at 5 Hz or a 63% increase in resonance frequency may be regarded as a surrogate of an FEV<sub>1</sub> decrease to determine airway hyperresponsiveness in asthma.

## Study Protocol

IOS was performed prior to spirometry. Airway responsiveness was assessed as the cumulative dose of leukotriene D<sub>4</sub> that caused a 20% decrease in FEV<sub>1</sub>, and a positive response was defined as ≤ 4.800 nmol of leukotriene D<sub>4</sub>. The diagnostic power of IOS parameters was evaluated with a receiver operating characteristic curve, from which we obtained the cutoff points for the sensitivities and specificities of the IOS parameters for asthma diagnosis.

Changes in IOS parameters corresponding to a 20% decrease in FEV<sub>1</sub> were calculated with the following formula:

$$R = \frac{(\ln D - \ln D_1)(R_2 - R_1)}{\ln D - \ln D_1} + R_1$$

where D<sub>1</sub> (or D<sub>2</sub>) is the cumulative dose that causes an R<sub>1</sub>% (or R<sub>2</sub>%) increase in IOS parameter, R<sub>1</sub> (or R<sub>2</sub>) is the variation (%) corresponding to the cumulative dose of X<sub>1</sub> (or X<sub>2</sub>), and D is the cumulative dose that causes R% increase in IOS parameter.

## Impulse Oscillometry

IOS (MS-IOS, Erich Jaeger, Friedberg, Germany) was conducted 5 min following leukotriene D<sub>4</sub> inhalation challenge, immediately prior to spirometry, based on the methods previously described.<sup>20</sup> The subject was seated upright with head straight and in slight extension. A nose clip was applied and the lips were tightly sealed around the mouthpiece to avoid gas leakage, and the subject firmly supported his or her cheeks with the palms of both hands. The

Table 1. Protocol of Leukotriene D<sub>4</sub> Inhalation Challenge Test

Step	Concentration (nmol/L × 10 <sup>4*</sup> )	Inhalation Time (s)	Inhalation Duration (s)	Dose (nmol)	Cumulative Dose (nmol)
1	1.6	1	0.315	0.075	0.075
2	1.6	3	0.315	0.225	0.300
3	3.2	5	0.375	0.900	1.200
4	3.2	10	0.750	3.600	4.800

\* 1 nmol leukotriene D<sub>4</sub> = 0.5 μg leukotriene D<sub>4</sub>.

IOS maneuver lasted for 40–60 seconds. The measured IOS parameters were respiratory impedance at 5 Hz (Z<sub>5</sub>), airway resistance at 5 Hz (R<sub>5</sub>), central airway resistance (R<sub>20</sub>), lung resistance at 5 Hz (X<sub>5</sub>), and resonance frequency.

**Spirometry**

Spirometry (Quark PFT, Cosmed, Rome, Italy) was performed per the joint recommendations of the American Thoracic Society and European Respiratory Society.<sup>21</sup> At least 3 (not more than 8) maneuvers were performed, with the variation between the best 2 maneuvers of < 5% or 150 mL in FVC and FEV<sub>1</sub>. The maximum FVC, FEV<sub>1</sub>, and PEF values are reported. The predicted values were calculated based on the normative values recommended by Zheng and Zhong.<sup>22</sup>

**Inhalation Challenge of Leukotriene D<sub>4</sub>**

The method for the leukotriene D<sub>4</sub> bronchial provocation test has been described previously.<sup>23,24</sup> Briefly, dilutions were delivered from a nebulizer (646, DeVilbiss Healthcare, Somerset, Pennsylvania) powered by compressed oxygen at 37.0 psi at 900 μL/min. Inhalation challenge using 16% ethanol dilution was performed for excluding the subjects hypersensitive to ethanol. Leukotriene D<sub>4</sub> challenge was started when FEV<sub>1</sub> decrease was < 20% and was restored to < 10% within 1 min. The initial and final cumulative dose of leukotriene D<sub>4</sub> was 0.075 nmol and 4.800 nmol, respectively, based on the 4-fold incremental steps.<sup>23,24</sup> Repetitive inhalation challenges were performed at an interval of 5 min (Table 1). These procedures were terminated in case of ≥ 20% FEV<sub>1</sub> decrease.

**Statistical Analysis**

Statistical analysis was performed with statistics software (SPSS 16.0, SPSS, Chicago, Illinois). Data are expressed as mean ± SD for normal distribution data, and as




Fig. 1. Subject enrollment.

median (IQR) for non-normal distribution data. Two-sided independent *t* tests for comparison on baseline levels were performed when normal distribution was detected; otherwise the 2-sided Mann-Whitney U test was employed. The diagnostic power of IOS parameters was assessed with the receiver operating characteristic curve, from which the area under the curve and 95% CI were derived. To study the diagnostic power of the combination of IOS parameters we calculated the assay sensitivity and specificity. A positive response was defined if either IOS parameter reached the positive threshold. *P* < .05 was considered as statistical significance.

**Results**

The recruitment of subjects is shown in Figure 1. Of 104 subjects who underwent screening, 74 with physician-diagnosed asthma and 25 healthy subjects were enrolled, and 62 subjects with asthma and 21 healthy subjects completed the assessment.

The anthropometric parameters, FVC (3.52 ± 0.81 L vs 3.61 ± 0.76 L, *P* = .53), and percent-of-predicted FVC (FVC%) (110.33 ± 15.71% vs 107.03 ± 12.97%, *P* = .43) did not differ significantly between subjects with asthma and normal subjects. The normal subjects had significantly higher FEV<sub>1</sub> (3.03 ± 0.61 L vs 2.53 ± 0.62 L, *P* = .001) and FEV<sub>1</sub>% (107.30 ± 11.54% vs 94.56 ± 15.20%, *P* = .001) at baseline. Compared with the healthy subjects, the subjects with asthma had significantly higher IOS values: Z<sub>5</sub> 4.54 (2.12) vs 3.10 ± 0.87 (*P* < .001), resonance frequency 10.61 (2.83) vs 8.63 ± 1.18 (*P* = .01),

IMPULSE OSCILLOMETRY FOR LEUKOTRIENE D<sub>4</sub> INHALATION CHALLENGE IN ASTHMA

Table 2. Changes in Major Impulse Oscillometry Parameters Prior to and Following Leukotriene D<sub>4</sub> Challenge

	Subjects With Asthma <i>n</i> = 62 (cm H <sub>2</sub> O/L/s)				Healthy Subjects <i>n</i> = 21 (cm H <sub>2</sub> O/L/s)			
	Pre	Post	Z	<i>P</i>	Pre	Post	Z	<i>P</i>
Z <sub>5</sub>	4.69 ± 2.18	7.97 ± 6.02	-6.075	< .001	3.10 ± 0.87	3.62 ± 1.82	-3.441	.001
R <sub>5</sub>	4.33 ± 2.34	8.30 ± 3.58	-6.712	< .001	2.95 ± 0.82	3.50 ± 1.81	-3.615	< .001
R <sub>20</sub>	3.77 ± 1.18	5.08 ± 1.60	-6.213*	< .001	2.36 ± 1.10	3.25 ± 0.98	-3.424	.001
Resonance frequency	9.34 ± 2.83	22.49 ± 14.29	-6.811	< .001	8.63 ± 1.18	9.32 ± 5.41	-2.850	.004
X <sub>5</sub>	-1.10 ± 0.74	-2.76 ± 3.25	-6.641	< .001	-0.84 ± 0.51	-1.10 ± 0.50	-1.929	.054

± Values are mean ± SD.  
\* Denotes t value.

Table 3. Change in Major Impulse Oscillometry Parameters Corresponding to a 20% Decrease in FEV<sub>1</sub>

	Change	
	Mean ± SD	Range
Z <sub>5</sub>	75.60 ± 46.23	-2.17 to 237.98
R <sub>5</sub>	65.56 ± 37.28	-0.88 to 172.35
Resonance frequency	88.88 ± 58.19	5.73 to 226.00
	Median	(IQR)
R <sub>20</sub>	26.83	(-17.59 to 168.56)
R <sub>5</sub> -R <sub>20</sub>	209.12	(-2,152.41 to 17,400.00)
X <sub>5</sub>	-137.66	(32.64 to 1,008.16)

Table 4. Diagnostic Power of Major Impulse Oscillometry Parameters

	Area Under the Curve	Standard Error	<i>P</i>	95% CI
Z <sub>5</sub>	0.821	0.052	< .001	0.720-0.923
R <sub>5</sub>	0.806	0.056	< .001	0.696-0.915
R <sub>20</sub>	0.595	0.067	.20	0.464-0.727
R <sub>5</sub> -R <sub>20</sub>	0.717	0.069	.003	0.581-0.852
X <sub>5</sub>	0.764	0.066	< .001	0.635-0.893
Resonance frequency, %	0.815	0.054	< .001	0.709-0.922

R<sub>5</sub> 4.40 (2.29) vs 2.95 ± 0.82 (*P* < .001), and R<sub>20</sub> 2.58 (1.10) vs 3.77 ± 1.18 (*P* < .001).

A significant change in IOS parameters was revealed (all *P* < .001) following leukotriene D<sub>4</sub> bronchial provocation test, when compared with the baseline levels, particularly in subjects with asthma, except for X<sub>5</sub> in healthy subjects (-0.84 ± 0.51 vs -1.10 ± 0.50), *P* = .054 (Table 2). There were significant outlier percentages observed in the increase of (R<sub>5</sub>-R<sub>20</sub>) and reduction of X<sub>5</sub> (Table 3).

The overall diagnostic power of IOS parameters, as evidenced by the area under the curve of the receiver operating characteristic curve, was the highest for Z<sub>5</sub>, followed by resonance frequency, R<sub>5</sub>, X<sub>5</sub> (R<sub>5</sub>-R<sub>20</sub>), and R<sub>20</sub>. Of all these parameters, Z<sub>5</sub>, resonance frequency, and R<sub>5</sub> showed the highest and acceptable diagnostic power (area under the curve 0.82, 0.82, and 0.81, respectively), while X<sub>5</sub> and (R<sub>5</sub>-R<sub>20</sub>) were excluded because of significant outlier values (Fig. 2, Table 4).

Based on the cutoff points obtained from the receiver operating characteristic curve, the positive thresholds of a 57%, 45%, 62%, 63% and 43% increase in Z<sub>5</sub>, R<sub>20</sub> (R<sub>5</sub>-R<sub>20</sub>), resonance frequency and R<sub>5</sub>, as well as a 77% reduction in X<sub>5</sub>, respectively, were defined. The 3 most sensitive indices, Z<sub>5</sub>, R<sub>5</sub>, and resonance frequency, were

associated with assay accuracies of 0.64, 0.61, and 0.57, respectively.

Overall, the IOS parameters yielded acceptable assay sensitivity and specificity, compared with FEV<sub>1</sub>. When the combinations of Z<sub>5</sub>, R<sub>5</sub>, and resonance frequency were employed for analysis, the assay sensitivity was increased, when compared with either individual IOS parameter. The tests were regarded positive as soon as the first single parameter reached the critical threshold. The 57% increase in Z<sub>5</sub> or 63% increase in resonance frequency yielded an improved assay accuracy of 0.60 (sensitivity 0.74, specificity 0.86) (Table 5).

**Discussion**

This was the first study, to our knowledge, that has investigated the positive threshold of IOS parameters and compared these indices with FEV<sub>1</sub>, a well established spirometric parameter, in subjects with asthma who underwent leukotriene D<sub>4</sub> inhalation challenge. Our data evidence that Z<sub>5</sub>, R<sub>5</sub>, and resonance frequency were characterized by the highest diagnostic power, with an increase of 57%, 43%, and 63% corresponding to a 20% decrease in FEV<sub>1</sub>, respectively. IOS was associated with a similar diagnostic power, compared with spirometry. The positive




Fig. 2. Receiver operating characteristic curves for impulse oscillometry parameters.  $Z_5$ ,  $R_5$ ,  $R_{20}$ , and  $X_5$  are defined in the text.  $Z_5$ ,  $R_5$ , and resonance frequency had the highest diagnostic power, as reflected by the area under curve of the receiver operating characteristic curve.

response of leukotriene D<sub>4</sub> bronchial provocation test, defined as a 57% increase in  $Z_5$  or 63% increase in resonance frequency, was associated with an assay accuracy of 0.6.

A reduced airway caliber in consequence of bronchospasm is linked to increase of airway resistance and decrease of capacitive lung resistance, which cannot be clinically measured by invasive approaches. Although spirometry has been well validated for bronchial provocation tests, IOS is expected to reflect changes in airway resistance, capacitive lung resistance, and inertance in a more spontaneous and physiologic manner. The test sig-

nals of IOS technique at low frequency (ie, 5 Hz) represent the total airway resistance. This is because the vibration energy may readily transmit throughout the respiratory tract. Contrarily, the energy at high frequency (ie, 20 Hz) represents central airway resistance, as the signal is shunted by the proximal airways. Furthermore, the difference between total and central airway resistance ( $R_5$ – $R_{20}$ ) reflects peripheral resistance, and the capacitive lung resistance at low frequency denotes the compliance of the lungs and chest wall. These suggest that IOS technique might be feasible for assessment of leukotriene D<sub>4</sub> bronchial provocation test.

The leukotriene D<sub>4</sub> inhalation challenge led to a significant change ( $P < .01$ ) in IOS parameters. The evidence that a significant reaction was shown following inhalation challenge, except for  $R_{20}$  and airway capacitance ( $X_5$ ), was consistent with our previous findings,<sup>25</sup> suggesting that stronger bronchoconstriction is associated with a higher airway resistance, as a consequence of reduced airway caliber. The FEV<sub>1</sub> decrease was postulated to vary approximately proportional to the increase in IOS parameters, except for  $X_5$ .

The positive threshold of IOS parameters among different studies remains largely inconclusive. Bohadana et al<sup>16</sup> reported a lower cumulative dose of carbachol and higher positive rate when using a 47% increase in mean resistance when the dose-response curve was employed. By using the average reaction in IOS parameters and linear regression model, Wang et al<sup>25</sup> reported that an 80% increase in resonance frequency, 50% increase in  $Z_5$  or  $R_5$ , or 100% increase in  $X_5$  could be regarded as significant. Pairon et al<sup>26</sup> reported an assay sensitivity of 0.75 and specificity of 0.76 for a 65% increase in total resistance for methacholine bronchial provocation test in active workers with normal baseline spirometry. They also showed that the positive threshold was 65% and 50% for elastance at

Table 5. Diagnostic Power of Major Impulse Oscillometry Parameters and FEV<sub>1</sub>

	Sensitivity	Specificity	Youden Index	Positive Likelihood Ratio	Negative Likelihood Ratio
PD <sub>57</sub> $Z_5$	0.6290	0.8571	0.4861	4.4017	0.4329
PD <sub>43</sub> $R_5$	0.7258	0.7619	0.4877	3.0483	0.3599
PD <sub>27</sub> $R_{20}$	0.4677	0.4762	−0.0561	0.8929	1.1178
PD <sub>62</sub> ( $R_5$ – $R_{20}$ )	0.7581	0.7143	0.4724	2.6535	0.3387
PD <sub>63</sub> resonance frequency	0.6129	0.8571	0.4700	4.2890	0.4516
PD <sub>77</sub> $X_5$	0.7097	0.7143	0.4240	2.4841	0.4064
$R_5 + Z_5$	0.7419	0.7619	0.5038	3.1160	0.3388
$R_5 +$ resonance frequency	0.7742	0.7619	0.5361	3.2516	0.2964
$Z_5 +$ resonance frequency	0.7419	0.8574	0.5993	5.2027	0.3010
PD <sub>20</sub> FEV <sub>1</sub>	0.8710	0.9048	0.7758	9.1492	0.1426

PD = provocation dose that causes the subscript value percent change.

10 Hz and resonance frequency: results similar to our study. Snashall et al<sup>27</sup> documented that, when compared with FEV<sub>1</sub>, Z<sub>10</sub> yielded a 2.7-times increase in the cumulative dose that caused a 20% decrease in Z<sub>10</sub> and the cumulative dose that caused a 20% decrease in FEV<sub>1</sub> might be regarded as equivalent in subjects who underwent histamine inhalation challenge. However, the airway capacitance was shown to have a greater diagnostic power in another study. By studying preschool children who underwent methacholine inhalation challenge, Jee et al<sup>28</sup> reported an assay sensitivity of 0.80 and a specificity of 0.83, corresponding to an 80% decrease in X<sub>5</sub>, particularly when compared using the area under curve with R<sub>5</sub> (0.87 vs 0.75). These data at least suggest that the various thresholds could have stemmed from different populations, settings, and the stimuli for the bronchial provocation tests.

R<sub>20</sub> was expected to reflect the changes in central airway resistance. It seemed reasonable that an insignificant increase in R<sub>20</sub> was evidenced, despite the presence of bronchospasm. From the physiological point of view, X<sub>5</sub> has relevance with regard to the reaction of peripheral airways. However, owing to a marked variation and outlier values following inhalation challenge, the change in X<sub>5</sub> was not useful when the baseline level was very small, and could even be zero from the mathematical background. It would have been more reasonable to argue that X<sub>5</sub> was not feasible to define the positive response of bronchospasm and should be excluded for further analysis.

The overall diagnostic power of IOS parameters was highest for Z<sub>5</sub>, followed by resonance frequency, R<sub>5</sub>, X<sub>5</sub> (R<sub>5</sub>–R<sub>20</sub>), and R<sub>20</sub>. Again, this has led us to conclude that neither the change in (R<sub>5</sub>–R<sub>20</sub>) nor in R<sub>20</sub> was reliable. Z<sub>5</sub>, resonance frequency, and R<sub>5</sub> were characterized by a similar diagnostic power (area under the curve 0.82, 0.82, and 0.81, respectively). An increase of 57%, 43%, and 63% in Z<sub>5</sub>, R<sub>5</sub>, and resonance frequency could be regarded as the positive threshold, based on the cutoff points derived from the receiver operating characteristic curve.

Two studies<sup>29,30</sup> have reported a higher assay sensitivity of IOS parameters, compared with spirometry, which is inconsistent with our findings. This could have stemmed from the difference in study design, leading to varying conclusions. Importantly, the positive response, defined as when any of the individual parameters (resonance frequency, Z<sub>5</sub>, or R<sub>5</sub>) reached the threshold, was characterized by a higher sensitivity. The sensitivity of 0.45 for resonance frequency, Z<sub>5</sub>, and R<sub>5</sub> was documented<sup>25</sup> in a study that also showed a higher sensitivity and specificity (0.70 and 0.88, respectively) when either individual parameter reached the positive threshold. This warranted the combination of, but not individual, parameters for assessment. There were 2 major factors that could have contributed to the distinction among the literatures. First, since the inclusion criteria differed, the results might have been

affected by the different proportion of subjects with asthma and healthy subjects, or those with different control status. Second, the various positive criteria of IOS parameter and the threshold have rendered it impossible to compare the data directly.

The limitations of IOS technique (ie, high inter-individual variability in X<sub>5</sub>, lower repeatability than spirometry, and the potential impact of posture) have been undeniably shown. Although most of these could not be temporarily resolved, further studies that explore the changes in IOS parameters in subjects with asthma under different control status and the comparison with miscellaneous measures are necessary.

## Conclusions

IOS is characterized by acceptable diagnostic power, compared with spirometry, for bronchial provocation tests, given the study design, in which spirometry was adopted as the gold standard for inhalation challenge test. Z<sub>5</sub>, resonance frequency, and R<sub>5</sub> are the IOS parameters that have the highest diagnostic power. Either a 57% increase in Z<sub>5</sub> or a 63% increase in resonance frequency may be regarded as a surrogate of FEV<sub>1</sub> decrease to determine airway hyper-responsiveness in asthma.

## ACKNOWLEDGMENT

We thank Hans-Juergen Smith, CareFusion, for his critical review of the manuscript and technical suggestions.

## REFERENCES

1. Drazen JM. Leukotrienes as mediators of airway obstruction. *Am J Respir Crit Care Med* 1998;158(5 Pt 3):S193-S200.
2. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. *Chest* 1997;111(2 Suppl):27S-34S.
3. Lee TH, Woszczek G, Farooque SP. Leukotriene E<sub>4</sub>: perspective on the forgotten mediator. *J Allergy Clin Immunol* 2009;124(3):417-421.
4. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The Anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. *Chest* 2001;119(5):1533-1546.
5. Baur X. Bronchial challenge tests. *Pneumologie* 2011;65(6):340-346.
6. Mulder A, Gauvreau GM, Watson RM, O'byrne PM. Effect of inhaled leukotriene D<sub>4</sub> on airway eosinophilia and airway hyper-responsiveness in asthmatic subjects. *Am J Respir Crit Care Med*. 1999;159(5 Pt 1):1562-1567.
7. Wood-Baker R, Town GI, Benning B, Holgate ST. The reproducibility and effect on non-specific airway responsiveness of inhaled prostaglandin D<sub>2</sub> and leukotriene D<sub>4</sub> in asthmatic subjects. *Br J Clin Pharmacol* 1995;39(2):119-123.
8. Schelfhout V, Van De Velde V, Pauwels R, Joos G. The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma: a comparison with leukotriene D<sub>4</sub> induced bronchoconstriction. *Pulm Pharmacol Ther* 2008; 21(2):276-284.

9. Smith LJ, Hanby LA, Lavins BJ, Simonson SG. A single dose of zafirlukast reduces LTD<sub>4</sub>-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy. *Ann Allergy Asthma Immunol* 1998;81(1):43-49.
10. Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A, Schnitz-Schuamann M, Lee TH. Increased urinary LTE<sub>4</sub> excretion following inhalation of LTC<sub>4</sub> and LTE<sub>4</sub> in asthmatic subjects. *Eur Respir J* 1994;7(5):907-913.
11. Deykin A, Belostotsky O, Hong C, Massaro AF, Lilly CM, Israel E. Exhaled nitric oxide following leukotriene E<sub>4</sub> and methacholine inhalation in patients with asthma. *Am J Respir Crit Care Med* 2000;162(5):1685-1689.
12. O'Shaughnessy TC, Georgiou P, Howland K, Dennis M, Compton CH, Barnes NC. Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D<sub>4</sub> (LTD<sub>4</sub>) challenge in normal volunteers. *Thorax* 1997;52(6):519-522.
13. Casas A, Gómez FP, Dahlén B, Roca J, Barbera JA, Dahlén SE, Rodriguez-Roison R. Leukotriene D<sub>4</sub>-induced hypoxaemia in asthma is mediated by the cys-leukotriene 1 receptor. *Eur Respir J* 2005;26(3):442-448.
14. Gyllfors P, Dahlén SE, Kumlin M, Larsson K, Dahlén B. Bronchial responsiveness to leukotriene D<sub>4</sub> is resistant to inhaled fluticasone propionate. *J Allergy Clin Immunol* 2006;118(1):78-83.
15. Gyllfors P, Kumlin M, Dahlén SE, Gaber F, Ehrns PO, Dahlén B. Relation between bronchial responsiveness to inhaled leukotriene D<sub>4</sub> and markers of leukotriene biosynthesis. *Thorax* 2005;60(11):902-908.
16. Bohadana AB, Peslin R, Megherbi SE, Teculescu D, Sauleau EA, Wild P, Pham QT. Dose-response slope of forced oscillation and forced expiratory parameters in bronchial challenge testing. *Eur Respir J* 1999;13(2):295-300.
17. Oostveen E, MacLeod D, Lorino H. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. *Eur Respir J* 2003;22(6):1026-1041.
18. Kim HY, Shin YH, Jung DW. Resistance and reactance in oscillation lung function reflect basal lung function and bronchial hyperresponsiveness respectively. *Respirology* 2009;14(7):1035-1041.
19. O'Byrne P, Bateman ED, Bousquet JD, Clark T, Ohta K, Paggiaro P, et al. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2006. <http://www.ginasthma.org/Guidelines/guidelines-resources.html>. Accessed September 20, 2013.
20. Smith HJ, Reinhold P, Goldman. Forced oscillation technique and impulse oscillometry. *Eur Respir J* 2005;31(Suppl):72-105.
21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al; ATS/ERS task force. Standardization of spirometry. *Eur Respir J* 2005;26(2):319-338.
22. Zheng JP, Zhong NS. Normative values of pulmonary function testing in Chinese adults. *Chin Med J* 2002;115(1):50-54.
23. Guan W, Zheng J, Gao Y, Jiang C, Xie Y, An J, et al. Leukotriene D<sub>4</sub> and methacholine bronchial provocation test for identifying leukotriene-responsiveness subtypes. *J Allergy Clin Immunol* 2013;131(2):332-338.
24. Guan W, Zheng J, Gao Y, Jiang C, An J, Yu X, Liu W. Leukotriene D<sub>4</sub> bronchial provocation test: methodology and diagnostic value. *Curr Med Res Opin* 2012;28(5):797-803.
25. Wang HY, An JY, Luo DF, Zheng JP. Implication of impulse oscillometry in the measurement of bronchial hyperresponsiveness. *Chin J Postgrad Med* 2006;29(1):39-41.
26. Pairon JC, Iwatsubo Y, Hubert C, Lorino H, Nouaigui H, Gharbi R, Brochard P. Measurement of bronchial responsiveness by forced oscillation technique in occupational epidemiology. *Eur Respir J* 1994;7(3):484-489.
27. Snashall PD, Parker S, Ten Haave P, Simmons D, Noble MI. Use of an impedance meter for measuring airways responsiveness to histamine. *Chest* 1991;99(5):1183-1185.
28. Jee HM, Kwak JH, Jung W, Han MY. Useful parameters of bronchial hyperresponsiveness measured with an impulse oscillometry in preschool children. *J Asthma* 2010;47(3):227-32.
29. Almosawi AI, Keung EJ, Gauvreau GM, Killian KJ. Assessing the sensitivity of IOS (Impulse Oscillation) compared to spirometry and plethysmography in detecting methacholine induced bronchoconstriction (abstract). *Am J Respir Crit Care Med* 2010;181:A4993.
30. Hira HS, Singh A. The site of airway obstruction among patients of bronchial asthma: role of impulse oscillometry (abstract). *Chest* 2008;134:5004.